Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for TELA Bio, Inc. (TELA : NSDQ)
 
 • Company Description   
TELA Bio Inc. is a commercial stage medical technology company. It is focused on the designing, developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices. TELA Bio Inc. is headquartered in Malvern, Pennsylvania.

Number of Employees: 123

 
 • Price / Volume Information   
Yesterday's Closing Price: $8.89 Daily Weekly Monthly
20 Day Moving Average: 21,866 shares
Shares Outstanding: 14.56 (millions)
Market Capitalization: $129.42 (millions)
Beta: 1.57
52 Week High: $16.53
52 Week Low: $7.23
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -7.49% 4.20%
12 Week -25.79% -18.41%
Year To Date -30.55% -15.14%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1 GREAT VALLEY PARKWAY SUITE 24
-
MALVERN,PA 19355
USA
ph: 484-320-2930
fax: -
ir@telabio.com http://www.telabio.com
 
 • General Corporate Information   
Officers
Antony Koblish - President; Chief Executive Officer and Director
Doug Evans - Chairman; Board of Directors
Roberto Cuca - Chief Operating Officer and Chief Financial Office
Megan Smeykal - Chief Accounting Officer and Controller
Kurt Azarbarzin - Director

Peer Information
TELA Bio, Inc. (CORR.)
TELA Bio, Inc. (RSPI)
TELA Bio, Inc. (CGXP)
TELA Bio, Inc. (BGEN)
TELA Bio, Inc. (GTBP)
TELA Bio, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 872381108
SIC: 3841
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 14.56
Most Recent Split Date: (:1)
Beta: 1.57
Market Capitalization: $129.42 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.60 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.47 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 12.89
Price/Cash Flow: -
Price / Sales: 4.07
EPS Growth
vs. Year Ago Period: -33.93%
vs. Previous Quarter: -27.12%
Sales Growth
vs. Year Ago Period: 40.05%
vs. Previous Quarter: -1.71%
ROE
03/31/22 - -155.13
12/31/21 - -106.93
09/30/21 - -84.60
ROA
03/31/22 - -55.28
12/31/21 - -46.96
09/30/21 - -42.22
Current Ratio
03/31/22 - 4.10
12/31/21 - 5.58
09/30/21 - 6.99
Quick Ratio
03/31/22 - 3.26
12/31/21 - 4.86
09/30/21 - 6.32
Operating Margin
03/31/22 - -113.15
12/31/21 - -112.94
09/30/21 - -121.27
Net Margin
03/31/22 - -113.15
12/31/21 - -112.94
09/30/21 - -121.27
Pre-Tax Margin
03/31/22 - -113.15
12/31/21 - -112.94
09/30/21 - -121.27
Book Value
03/31/22 - 0.69
12/31/21 - 1.39
09/30/21 - 1.92
Inventory Turnover
03/31/22 - 1.56
12/31/21 - 1.79
09/30/21 - 1.99
Debt-to-Equity
03/31/22 - 3.15
12/31/21 - 1.57
09/30/21 - 1.13
Debt-to-Capital
03/31/22 - 75.93
12/31/21 - 61.04
09/30/21 - 53.04
 

Powered by Zacks Investment Research ©